January 1, 1970 - HMDCF
HUTCHMED (China) Limited: A Deep Dive into Recent Financials
HUTCHMED (China) Limited (HMDCF) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in Hong Kong and internationally.
HUTCHMED's recent financial data reveals some interesting trends. Let's break down some key highlights:
Key Highlights
| Metric | Value |
|---|---|
| Market Cap | $3,256,652,032 |
| Revenue (TTM) | $837,998,976 |
| Net Income (TTM) | -$41,743,500 |
| Cash and Short Term Investments | $886,336,000 |
| Total Debt | $134,490,000 |
Source: Financial data extracted on 2024-06-18.
Revenue and Net Income Trend
The chart above illustrates the fluctuating nature of HUTCHMED's revenue and net income. Further analysis is required to understand the factors driving these changes, such as product sales, research and development expenses, and collaborations.
Pipeline and Collaborations
HUTCHMED has a robust pipeline of targeted therapies and immunotherapies for various types of cancer. The company also has strategic collaborations with several major pharmaceutical companies, including AstraZeneca and Eli Lilly.
Future Outlook
The future of HUTCHMED depends on the successful development and commercialization of its pipeline candidates. The company's collaborations with established pharmaceutical players provide access to resources and expertise that can accelerate growth.
"Fun Fact: HUTCHMED was founded in 2000 as Hutchison China MediTech Limited and later changed its name to HUTCHMED (China) Limited in May 2021."
